# MRA and ARB Treatment in Screening of Primary Aldosteronism

> **NCT04185857** · — · COMPLETED · sponsor: **University Hospital Padova** · enrollment: 50 (actual)

## Conditions studied

- Primary Aldosteronism Due to Aldosterone Producing Adenoma

## Interventions

- **DRUG:** canrenone 50-100 mg orally once a day
- **DRUG:** olmesartan 10-20 mg orally once a day

## Key facts

- **NCT ID:** NCT04185857
- **Lead sponsor:** University Hospital Padova
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-25
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185857, "MRA and ARB Treatment in Screening of Primary Aldosteronism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04185857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*